Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Raab MS"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 36
Tytuł:
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Autorzy:
Kauer J; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
Freundt EP; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Schmitt A; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Weinhold N; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Mai EK; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany.
Müller-Tidow C; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Goldschmidt H; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; GMMG Study Group at University Hospital Heidelberg, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Raab MS; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; National Centre for Tumour Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Kriegsmann K; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Laborarztpraxis, Laborarztpraxis Rhein-Main MVZ GbR, Limbach Gruppe SE, Frankfurt Am Main, Germany.
Sauer S; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 21; Vol. 23 (1), pp. 1132. Date of Electronic Publication: 2023 Nov 21.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Heterocyclic Compounds*/therapeutic use
Multiple Myeloma*/drug therapy
Multiple Myeloma*/diagnosis
Peripheral Blood Stem Cell Transplantation*
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Hematopoietic Stem Cell Mobilization/methods ; Lenalidomide/therapeutic use ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
Autorzy:
Leypoldt LB; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Gavriatopoulou M; Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Besemer B; Department of Hematology, Oncology, Immunology, Rheumatology, University Hospital of Tuebingen, 72076 Tuebingen, Germany.
Salwender H; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, 22763 Hamburg, Germany.
Raab MS; Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Nogai A; Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, 12200 Berlin, Germany.
Khandanpour C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.; Department of Hematology and Oncology, University Hospital Schleswig-Holstein and University of Lübeck, 23538 Lübeck, Germany.
Runde V; Department of Hematology, Oncology and Palliative Care, Wilhelm-Anton-Hospital, 47574 Goch, Germany.
Jauch A; Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Zago M; Center for Clinical Trials, University Hospital of Tuebingen, 72070 Tuebingen, Germany.
Martus P; Department of Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University of Tuebingen, 72076 Tuebingen, Germany.
Goldschmidt H; Internal Medicine V and GMMG-Study Group, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Bokemeyer C; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Weisel KC; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Sep 21; Vol. 15 (18). Date of Electronic Publication: 2023 Sep 21.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The prognostic significance of [ F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs).
Autorzy:
Sachpekidis C; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany. .
Merz M; Department of Hematology and Cell Therapy, University of Leipzig, Leipzig, Germany.; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Raab MS; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bertsch U; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Weru V; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kopp-Schneider A; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Goldschmidt H; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Dimitrakopoulou-Strauss A; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2021 Oct 09; Vol. 11 (1), pp. 100. Date of Electronic Publication: 2021 Oct 09.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Autorzy:
Klein EM; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; Department of Internal Medicine 5, Klinikum Nuremberg, Paracelsus Medical University, 90419 Nuremberg, Germany.
Tichy D; Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Salwender HJ; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, 22763 Hamburg, Germany.
Mai EK; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Duerig J; Department of Hematology, University Clinic Essen, 45147 Essen, Germany.
Weisel KC; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Bertsch U; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany.
Akhavanpoor M; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Besemer B; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, 72076 Tübingen, Germany.
Munder M; Department of Internal Medicine III, University Medical Center Mainz, 55131 Mainz, Germany.
Lindemann HW; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, 58097 Hagen, Germany.
Hose D; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Seckinger A; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Luntz S; Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120 Heidelberg, Germany.
Jauch A; Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Elmaagacli A; Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, 20099 Hamburg, Germany.
Fuhrmann S; Department of Hematology and Oncology, Helios Hospital Berlin Buch, 13125 Berlin, Germany.
Brossart P; Department of Internal Medicine, Oncology, Hematology, Immuno-Oncology and Rheumatology/Clinical Immunology, University Hospital Bonn, 53127 Bonn, Germany.
Goerner M; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, 33604 Bielefeld, Germany.
Bernhard H; Internal Medicine V, Klinikum Darmstadt, 64283 Darmstadt, Germany.
Raab MS; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Blau IW; Medical Clinic, Charité University Medicine Berlin, 13353 Berlin, Germany.
Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, 09116 Chemnitz, Germany.
Scheid C; Department of Internal Medicine I, University Hospital Cologne, 50937 Cologne, Germany.
Goldschmidt H; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany.
On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Sep 28; Vol. 13 (19). Date of Electronic Publication: 2021 Sep 28.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
Autorzy:
Baertsch MA; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.
Fougereau M; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.
Hielscher T; Division of Biostatistics, German Cancer Research Center, 69121 Heidelberg, Germany.
Sauer S; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.
Breitkreutz I; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.
Jordan K; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.
Müller-Tidow C; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University Hospital, 69121 Heidelberg, Germany.
Goldschmidt H; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University Hospital, 69121 Heidelberg, Germany.
Raab MS; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, 69121 Heidelberg, Germany.
Hillengass J; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.; Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Giesen N; Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69121 Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, 69121 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Sep 20; Vol. 13 (18). Date of Electronic Publication: 2021 Sep 20.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop.
Autorzy:
Lutz R; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Friedrich M; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Raab MS; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Weinhold N; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Goldschmidt H; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Aug 18; Vol. 13 (16). Date of Electronic Publication: 2021 Aug 18.
Typ publikacji:
Congress
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pathway-Directed Therapy in Multiple Myeloma.
Autorzy:
John L; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Krauth MT; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Podar K; Department of Internal Medicine, Karl Landsteiner University of Health Sciences, Mitterweg 10, 3500 Krems an der Donau, Austria.
Raab MS; Department of Internal Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.; CCU Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Apr 01; Vol. 13 (7). Date of Electronic Publication: 2021 Apr 01.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Autorzy:
Knauf W; Centrum Haematologie & Onkologie Bethanien, Frankfurt, Germany.
Dingeldein G; Onkologische Schwerpunktpraxis, Darmstadt, Germany.
Schlag R; Hämatologisch-Onkologische Schwerpunktpraxis, Würzburg, Germany.
Welslau M; Onkologische Praxis, Aschaffenburg, Germany.
Moehler T; IQVIA, Frankfurt, Germany.
Terzer T; Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Walter S; Koordinierungszentrum für klinische Studien Heidelberg, FRG, Heidelberg, Germany.
Habermehl C; Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Kunz C; Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Goldschmidt H; Department of Medicine V, University of Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Raab MS; Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Corporate Authors:
BPV trial group
Źródło:
European journal of haematology [Eur J Haematol] 2020 Aug; Vol. 105 (2), pp. 116-125. Date of Electronic Publication: 2020 May 26.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Biomarkers, Tumor ; Bortezomib/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Neoplasm Staging ; Prednisone/administration & dosage ; Prognosis ; Progression-Free Survival ; Renal Insufficiency/diagnosis ; Renal Insufficiency/etiology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Can F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
Autorzy:
Sachpekidis C; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.
Kopp-Schneider A; Department of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Merz M; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Jauch A; Institute for Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Raab MS; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Goldschmidt H; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Dimitrakopoulou-Strauss A; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 May 23; Vol. 12 (5). Date of Electronic Publication: 2020 May 23.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
Autorzy:
Mohty M; Department of Haematology, Hôpital Saint-Antoine, Universite Pierre & Marie Curie, INSERM UMRs 938, Paris, France.
Cavo M; Seràgnoli Institute of Haematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.
Fink L; Kantar Health, Paris, France.
Gonzalez-McQuire S; Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Leleu H; Public Health Expertise, Paris, France.
Mateos MV; Haematology Department, University Hospital of Salamanca/Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Raab MS; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Schoen P; Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Yong K; Department of Haematology, University College London, London, UK.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2019 Aug; Vol. 103 (2), pp. 107-115. Date of Electronic Publication: 2019 Jun 18.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Multiple Myeloma/*mortality
Age Factors ; Cause of Death ; Combined Modality Therapy ; Comorbidity ; Disease Management ; Europe/epidemiology ; Female ; Humans ; Male ; Multiple Myeloma/diagnosis ; Multiple Myeloma/epidemiology ; Multiple Myeloma/therapy ; Neoplasm Staging ; Outcome Assessment, Health Care ; Population Surveillance ; Practice Patterns, Physicians' ; Retrospective Studies ; Risk Factors ; Symptom Assessment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.
Autorzy:
Campa D; a Department of Biology , University of Pisa , Pisa , Italy.
Martino A; b Genomic Epidemiology Group, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Macauda A; a Department of Biology , University of Pisa , Pisa , Italy.; b Genomic Epidemiology Group, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Dudziński M; c Hematology Department , Teaching Hospital No 1 , Rzeszów , Poland.
Suska A; d Department of Hematology , Jagiellonian University Medical College , Cracow , Poland.
Druzd-Sitek A; e Lymphoma Department , Centre of Oncology-Institute of Maria Skłodowska-Curie , Warsaw , Poland.
Raab MS; f Department of Internal Medicine V , Heidelberg University Hospital , Heidelberg , Germany.; g Max-Eder Research Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Moreno V; h Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), IDIBELL, CIBERESP and Department of Clinical Sciences, Faculty of Medicine , University of Barcelona , Barcelona , Spain.
Huhn S; i Molecular Biology Laboratory, Section of Multiple Myeloma, Department of Internal Medicine V , Heidelberg University Hospital , Heidelberg , Germany.
Butrym A; j Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology , Wroclaw Medical University , Wroclaw , Poland.
Sainz J; k PTS Granada , Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government , Granada , Spain.; l Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves , Granada , Spain.; m Pharmacogenetics Unit. Instituto de Investigación Biosanitaria de Granada (Ibs. Granada) , Hospitales Universitarios de Granada / Universidad de Granada , Granada , Spain.
Szombath G; n Department of Intrenal Medicine , Semmelweis University , Budapest , Hungary.
Rymko M; o Department of Haematology , Copernicus Town Hospital of Torun , Torun , Poland.
Marques H; p Life and Health Sciences Research Institute (ICVS), School of Health Sciences , University of Minho , Braga , Portugal.
Lesueur F; q INSERM U900 , Paris , France.; r Institut Curie , Paris , France.; s Mines ParisTech , Fontainebleau , France.; t PSL University , Paris , France.
Vangsted AJ; u Department of Hematology , Copenhagen University Hospital , Rigshospitalet , Denmark.
Vogel U; v National Research Centre for the Working Environment , Denmark.
Kruszewski M; w Department of Hematology , University Hospital , Bydgoszcz , Poland.
Subocz E; x Department of Haematology , Military Institute of Medicine , Warsaw , Poland.
Buda G; y Hematology Unit, Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.
Iskierka-Jażdżewska E; z Department of Hematology, Copernicus Memorial Hospital , Medical University of Lodz , Lodz , Poland.
Ríos R; k PTS Granada , Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government , Granada , Spain.; l Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves , Granada , Spain.; m Pharmacogenetics Unit. Instituto de Investigación Biosanitaria de Granada (Ibs. Granada) , Hospitales Universitarios de Granada / Universidad de Granada , Granada , Spain.
Merz M; f Department of Internal Medicine V , Heidelberg University Hospital , Heidelberg , Germany.
Schöttker B; aa Division of Clinical Epidemiology and Aging Research , German Cancer Research Center (DKFZ) , Heidelberg , Germany.; ab Network Aging Research (NAR) , University of Heidelberg , Heidelberg , Germany.
Mazur G; j Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology , Wroclaw Medical University , Wroclaw , Poland.
Perrial E; ac Cancer Research Center of Lyon, INSERM 1052/CNRS 5286 , University of Lyon , Lyon , France.
Martinez-Lopez J; ad Hospital 12 de Octubre , Complutense University, CNIO, CIBERONC , Madrid , Spain.
Butterbach K; ab Network Aging Research (NAR) , University of Heidelberg , Heidelberg , Germany.
García Sanz R; ae Department of Hematology , University Hospital of Salamanca , Salamanca , Spain.
Goldschmidt H; f Department of Internal Medicine V , Heidelberg University Hospital , Heidelberg , Germany.; af National Center for Tumor Diseases (NCT) , Heidelberg , Germany.
Brenner H; aa Division of Clinical Epidemiology and Aging Research , German Cancer Research Center (DKFZ) , Heidelberg , Germany.; ab Network Aging Research (NAR) , University of Heidelberg , Heidelberg , Germany.; ag Division of Preventive Oncology , National Center for Tumor Diseases (NCT) German Cancer Research Center (DKFZ) , Heidelberg , Germany.; ah German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Jamroziak K; ai Department of Hematology , Institute of Hematology and Transfusion Medicine , Warsaw , Poland.
Reis RM; p Life and Health Sciences Research Institute (ICVS), School of Health Sciences , University of Minho , Braga , Portugal.; aj ICVS/3B's - PT Government Associate Laboratory , Braga/Guimarães , Portugal.; ak Barretos Cancer Hospital , Molecular Oncology Research Center , S. Paulo , Brazil.
Kadar K; n Department of Intrenal Medicine , Semmelweis University , Budapest , Hungary.
Dumontet C; ac Cancer Research Center of Lyon, INSERM 1052/CNRS 5286 , University of Lyon , Lyon , France.
Wątek M; al Department of Hematology , Holy Cross Oncology Center , Kielce , Poland.
Haastrup EK; am Department of Clinical Immunology , Copenhagen University Hospital , Rigshospitalet, Copenhagen , Denmark.
Helbig G; an Department of Hematology and Bone Marrow Transplantation , Medical University of Silesia , Katowice , Poland.
Jurczyszyn A; d Department of Hematology , Jagiellonian University Medical College , Cracow , Poland.
Jerez A; ao Department of Hematology , University Hospital Morales Meseguer, IMIB , Murcia , Spain.
Varkonyi J; n Department of Intrenal Medicine , Semmelweis University , Budapest , Hungary.
Barington T; ap Department of Clinical Immunology , Odense University Hospital , Odense , Denmark.
Grzasko N; aq Department of Hematology , St. John's Cancer Center , Lublin , Poland.; ar Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
Zaucha JM; as Department of Hematology , Sea Hospital , Gdynia , Poland.
Andersen V; at IRS-Center Sønderjylland , Aabenraa , Denmark.; au Institute of Molecular Biology, University of Southern Denmark , Odense , Denmark.
Zawirska D; av Department of Haematology , University Hospital of Cracow , Cracow , Poland.
Canzian F; b Genomic Epidemiology Group, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Jul; Vol. 60 (7), pp. 1803-1811. Date of Electronic Publication: 2019 Jan 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Polymorphism, Genetic*
Biomarkers, Tumor/*genetics
Immunoglobulin Class Switching/*genetics
Multiple Myeloma/*etiology
Multiple Myeloma/*mortality
Adult ; Aged ; Case-Control Studies ; Cohort Studies ; Cytidine Deaminase/genetics ; DNA Ligase ATP/genetics ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Humans ; Lymphocyte Activation ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Prognosis ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Autorzy:
Hose D; Labor für Myelomforschung, Universitätsklinikum Heidelberg, Heidelberg, Germany.; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Beck S; Labor für Myelomforschung, Universitätsklinikum Heidelberg, Heidelberg, Germany.; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Salwender H; Department of Internal Medicine II, Asklepios Klinik Altona, Hamburg, Germany.
Emde M; Labor für Myelomforschung, Universitätsklinikum Heidelberg, Heidelberg, Germany.; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Bertsch U; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Kunz C; Deutsches Krebsforschungszentrum, Abteilung für Biostatistik, Heidelberg, Germany.
Scheid C; Department I of Internal Medicine, University of Cologne, Cologne, Germany.
Hänel M; Department of Internal Medicine III, Klinikum Chemnitz GmbH, Chemnitz, Germany.
Weisel K; Department of Hematology, Oncology and Immunology, University of Tübingen, Tübingen, Germany.
Hielscher T; Deutsches Krebsforschungszentrum, Abteilung für Biostatistik, Heidelberg, Germany.
Raab MS; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Goldschmidt H; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany.
Jauch A; Universität Heidelberg, Institut für Humangenetik, Heidelberg, Germany.
Moreaux J; IGH, CNRS, University of Montpellier, Montpellier, France.; Department of Biological Hematology, CHU Montpellier, Montpellier, France.
Seckinger A; Labor für Myelomforschung, Universitätsklinikum Heidelberg, Heidelberg, Germany. .; Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2019 Jun 26; Vol. 12 (1), pp. 65. Date of Electronic Publication: 2019 Jun 26.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma/*diagnosis
Multiple Myeloma/*drug therapy
Plasma Cells/*pathology
Gene Expression Profiling ; Humans ; In Situ Hybridization, Fluorescence ; Induction Chemotherapy ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Precision Medicine ; Prognosis ; Prospective Studies ; Risk Assessment ; Survival Analysis ; Transcriptome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Autorzy:
Salwender H; Asklepios Hospital Hamburg, Altona, Hematology, Oncology and Palliative Care, 22763, Hamburg, Germany. .
Bertsch U; University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Weisel K; University Hospital Tuebingen, Tuebingen, Germany.; University Hospital Hamburg Eppendorf, Hamburg, Germany.
Duerig J; University Hospital Essen, Essen, Germany.
Kunz C; German Cancer Research Center Heidelberg, Heidelberg, Germany.
Benner A; German Cancer Research Center Heidelberg, Heidelberg, Germany.
Blau IW; Charité Universitaetsmedizin Berlin, Berlin, Germany.
Raab MS; University Hospital Heidelberg, Heidelberg, Germany.
Hillengass J; University Hospital Heidelberg, Heidelberg, Germany.
Hose D; University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Huhn S; University Hospital Heidelberg, Heidelberg, Germany.
Hundemer M; University Hospital Heidelberg, Heidelberg, Germany.
Andrulis M; Institute of Pathology, Klinikum Ludwigshafen, Ludwigshafen am Rhein, Germany.
Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Seidel-Glaetzer A; Cordination Center for Clinical Trials, University of Heidelberg (KKS), Heidelberg, Germany.
Lindemann HW; Kath. Krankenhaus Hagen, Hagen, Germany.
Hensel M; Mannheimer Onkologie Praxis, Mannheim, Germany.
Fronhoffs S; Zentrum fuer ambulante Haematologie und Onkologie Siegburg, Siegburg, Germany.
Martens U; SLK Klinikum Heilbronn, Heilbronn, Germany.
Hansen T; University Hospital Hamburg Eppendorf, Hamburg, Germany.
Wattad M; Ev. Krankenhaus Essen-Werden, Essen, Germany.
Graeven U; Krankenhaus Maria Hilf Moenchengladbach, Moenchengladbach, Germany.
Munder M; University Medical Center Mainz, Mainz, Germany.
Fenk R; University Hospital Duesseldorf, Dusseldorf, Germany.
Haenel M; Klinikum Chemnitz, Chemnitz, Germany.
Scheid C; University Hospital Koeln, Cologne, Germany.
Goldschmidt H; University Hospital Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 May 28; Vol. 19 (1), pp. 504. Date of Electronic Publication: 2019 May 28.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antibodies, Monoclonal, Humanized/*administration & dosage
Bortezomib/*administration & dosage
Dexamethasone/*administration & dosage
Lenalidomide/*administration & dosage
Melphalan/*administration & dosage
Multiple Myeloma/*therapy
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Bortezomib/therapeutic use ; Consolidation Chemotherapy ; Dexamethasone/therapeutic use ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Induction Chemotherapy ; Lenalidomide/therapeutic use ; Maintenance Chemotherapy ; Male ; Melphalan/therapeutic use ; Middle Aged ; Prospective Studies ; Quality of Life ; Research Design ; Survival Analysis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
Autorzy:
Rasche L; Department of Internal Medicine 2, University Hospital of Würzburg, 97080 Würzburg, Germany. Rasche_.; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Rasche_.
Kortüm KM; Department of Internal Medicine 2, University Hospital of Würzburg, 97080 Würzburg, Germany. Kortuem_.
Raab MS; Department of Internal Medicine V, University Hospital of Heidelberg, 69120 Heidelberg, Germany. Marc.Raab@med.uni-heidelberg.de.
Weinhold N; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. .; Department of Internal Medicine V, University Hospital of Heidelberg, 69120 Heidelberg, Germany. .
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2019 Mar 12; Vol. 20 (5). Date of Electronic Publication: 2019 Mar 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma/*pathology
Multiple Myeloma/*therapy
Antibodies, Monoclonal/therapeutic use ; Humans ; Immunotherapy/methods ; Mutation/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.
Autorzy:
Lehners N; a Department of Internal Medicine V , University Hospital Heidelberg , Heidelberg , Germany.; b Max-Eder-Group Experimental Therapies for Hematologic Malignancies , German Cancer Research Center (DKFZ) and University Hospital Heidelberg , Heidelberg , Germany.
Ellert E; c Institute for Pathology, Ludwigshafen Hospital , Ludwigshafen , Germany.
Xu J; b Max-Eder-Group Experimental Therapies for Hematologic Malignancies , German Cancer Research Center (DKFZ) and University Hospital Heidelberg , Heidelberg , Germany.; d Institute for Pathology, University Hospital Heidelberg , Heidelberg , Germany.
Hillengass J; a Department of Internal Medicine V , University Hospital Heidelberg , Heidelberg , Germany.
Leichsenring J; d Institute for Pathology, University Hospital Heidelberg , Heidelberg , Germany.
Stenzinger A; d Institute for Pathology, University Hospital Heidelberg , Heidelberg , Germany.
Goldschmidt H; a Department of Internal Medicine V , University Hospital Heidelberg , Heidelberg , Germany.; e National Center for Tumor Diseases , Heidelberg , Germany.
Andrulis M; c Institute for Pathology, Ludwigshafen Hospital , Ludwigshafen , Germany.; d Institute for Pathology, University Hospital Heidelberg , Heidelberg , Germany.
Raab MS; a Department of Internal Medicine V , University Hospital Heidelberg , Heidelberg , Germany.; b Max-Eder-Group Experimental Therapies for Hematologic Malignancies , German Cancer Research Center (DKFZ) and University Hospital Heidelberg , Heidelberg , Germany.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2018 Nov; Vol. 59 (11), pp. 2660-2669. Date of Electronic Publication: 2018 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Cellular Senescence*
Cell Transformation, Neoplastic/*metabolism
Plasma Cells/*metabolism
Proto-Oncogene Proteins/*biosynthesis
Adult ; Aged ; Aged, 80 and over ; Cell Transformation, Neoplastic/pathology ; Cyclin-Dependent Kinase Inhibitor p21/biosynthesis ; Cyclin-Dependent Kinase Inhibitor p27/biosynthesis ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Monoclonal Gammopathy of Undetermined Significance/metabolism ; Monoclonal Gammopathy of Undetermined Significance/pathology ; Multiple Myeloma/metabolism ; Multiple Myeloma/pathology ; Plasma Cells/pathology ; Smoldering Multiple Myeloma/metabolism ; Smoldering Multiple Myeloma/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 36

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies